Safety, Tolerability, and Efficacy of IA Verapamil in the Treatment of Joint Pain in Subjects With Osteoarthritis of the Knee

CS-201: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Intra-Articular Verapamil in the Treatment of JoinT Pain in Subjects With Osteoarthritis of the Knee

This is a randomized, double-blind, placebo-controlled, multi-center study to evaluate the safety, tolerability, and efficacy of Intra-Articular (IA) verapamil in the treatment of joint pain in patients with knee osteoarthritis (OA). Subjects will discontinue all analgesic medications for the entire duration of the study, except for acetaminophen (taken on an as needed basis at no more than 2 g/day). At visit 2, subjects who meet all entry criteria will be randomized to receive a single injection of IA verapamil or IA placebo at a ratio of 1:1. Treatments will be given with fluoroscopy or ultrasound to confirm needle placement. Subjects will be monitored for blood pressure and heart rate (sitting and standing) for at least 1 hour post-injection. Subjects will be evaluated at weeks 1, 2, 3, 4, 6, 8, and 12 after treatment.

Study Overview

• Status: Terminated
• Conditions: Osteoarthritis of the Knee
• Intervention / Treatment: Drug: Placebo; Drug: Verapamil

• Study Type: Interventional
• Enrollment (Actual): 81
• Phase: Phase 2; Phase 1

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 35 years to 75 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

Subjects must meet all of the following inclusion criteria to participate in the study:

1. Be 35-75 years of age and in good general medical and psychological health.
2. Be able to speak, read, write, and understand English, understand the consent form, complete study-related procedures, and communicate with the study staff.

3. Have OA of at least 1 knee (target knee) for at least 6 months and meet all the following criteria:

   • OA documented by standing X-rays anterior-posterior patella-femoral view taken within 1 month of screening visit indicating Kellgren-Lawrence Grade 2 to early-stage Grade 4 radiographic stage of the knee;

   • Have pain associated with OA of the target knee for at least 25 of the last 30 days; c. Meet the American College of Rheumatology clinical classification criteria, defined as having pain in the target knee and at least 3 of the following 6 items:

     • Age > 50;
     • Morning stiffness <30 minutes;
     • Crepitus on active motion;
     • Bony tenderness;
     • Bony enlargement;
     • No palpable warmth of synovium.
4. Target knee does not have any type of orthopedic and/or prosthetic device.
5. Based on standard physical examination of the target knee, does not have any neurovascular deficits, any skin abnormalities, any meniscal abnormalities, or any ligament instability.
6. At treatment visit 2 prior to randomization, have a score of at least 20 on the WOMAC pain subscale (questions 1-5) for the target knee and an in-clinic average pain intensity score of at least 4/10 on the 0-10 NRS for the 24-hour recall.
7. Be willing to maintain any present stable treatment modalities (e.g., acupuncture or physical therapy) and be willing to refrain from initiating any new treatment modalities.
8. Be willing to stop taking nonsteroidal anti-inflammatory drugs (NSAIDs) and opioids for the duration of the study.
9. If female of child-bearing potential (ie, not medically or surgically sterilized or not post-menopausal more than 1 year) or fertile male with sexual partner of childbearing potential, be willing to use adequate and reliable contraception throughout the study (eg, abstinence or barrier with additional spermicidal foam or jelly, or the use of intrauterine device or hormonal contraception by female subjects and partners of male subjects).
10. Not be enrolled in any other clinical trial and not have used any investigational drug within 1 month.

Exclusion Criteria:

Subjects who meet any of the following criteria will not be eligible to participate:

1. Have a Kellgren-Lawrence Grade 1 radiographic stage of the knee or have Kellgren-Lawrence Grade 4 radiographic end stage of the knee with bone on bone, ie, less than 2 mm joint space.
2. Be a candidate for knee replacement within next 6 months.
3. Have a body mass index > 35 kg/m2.
4. Have a Hospital Anxiety and Depression Scale score >12 on either subscale or have an established history of major depressive disorder not controlled with medication.
5. Have, in the Investigator's opinion, clinically significant abnormalities in clinical laboratory tests (hematology, clinical labs, urinalysis).
6. Have a positive urine drug test for illegal drug substances at screening.
7. Have, in the Investigator's opinion, clinically significant abnormalities in electrocardiogram readings
8. If a female of childbearing potential, have a positive pregnancy test at screening.
9. Have significant pain outside the target knee, including significant hip or back pain (bilateral knee OA will be allowed as long as target knee pain can be distinguished from contralateral knee pain and contralateral knee does not require treatment).
10. Have pain affecting the target knee that is due to any etiology other than OA.
11. Have documented history of inflammatory arthritis, including rheumatoid arthritis.
12. Have a meniscal tear in the target knee.
13. Have had viscosupplementation with hyaluronic acid products within 6 months prior to screening.
14. Have failed to respond to prior treatment with viscosupplementation with hyaluronic acid products.
15. Have had IA corticosteroid injections within 12 weeks or intramuscular or oral steroids within 4 weeks prior to screening.
16. Have had surgery of the target knee within 6 months prior to screening.
17. Have used opioids 4 or more days per week during in the past month prior to screening.
18. Are allergic to, or intolerant of, acetaminophen.
19. Have used verapamil within the past 4 weeks or are allergic or intolerant to verapamil.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Single Group Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Verapamil; Subjects will be randomized to receive a single injection of IA Verapamil or IA Placebo at a ratio of 1:1.	Drug: Verapamil
Placebo Comparator: Placebo; Subjects will be randomized to receive a single injection of IA Verapamil or IA Placebo at a ratio of 1:1.	Drug: Placebo

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Compare Efficacy of Verapmil vs Placebo at Week 4	To compare the efficacy of IA verapamil versus IA placebo for pain relief using the Western Ontario and McMaster Universities Arthritis Index (WOMAC) at week 4.	4 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Compare Efficacy of Verapamil to Placebo Compared to Baseline	To compare the efficacy of IA verapamil and IA placebo using change from baseline in the following: • WOMAC total and subscale scores for pain, function, and stiffness at each visit	13 weeks
Compare Efficacy of Verapamil to Placebo Compared to Baseline	To compare the efficacy of IA verapamil and IA placebo using change from baseline in the following: • WOMAC pain subscale as measured from 2 to 12 weeks post-treatment using an AUC approach	13 weeks
Compare Efficacy of Verapamil to Placebo Compared to Baseline	To compare the efficacy of IA verapamil and IA placebo using change from baseline in the following: • In-clinic 24-hour recall pain intensity using the 0-10 numerical rating scale (NRS) at each visit	13 weeks
Compare Efficacy of Verapamil to Placebo Compared to Baseline	To compare the efficacy of IA verapamil and IA placebo using change from baseline in the following: • Difference in the current in-clinic pain intensity using the 0-10 NRS before and after exercise at each visit	13 weeks
Compare Efficacy of Verapamil to Placebo Compared to Baseline	To compare the efficacy of IA verapamil and IA placebo using change from baseline in the following: • Response rate	13 weeks
Compare Efficacy of Verapamil to Placebo Compared to Baseline	To compare the efficacy of IA verapamil and IA placebo using change from baseline in the following: • Patient Global Impression of Change (PGIC)	13 weeks
Compare Efficacy of Verapamil to Placebo Compared to Baseline	To compare the efficacy of IA verapamil and IA placebo using change from baseline in the following: • Rescue medication use	13 weeks
Number of Subjects With Adverse Events	Compare the safety of IA verapamil versus IA placebo using adverse events (AEs) as a comparator	13 weeks

Collaborators and Investigators

• Sponsor: Calosyn Pharma, Inc.
• Collaborators: Health Decisions

Study record dates

Study Major Dates

• Study Start: April 1, 2012
• Primary Completion (Actual): February 1, 2013

Study Registration Dates

• First Submitted: July 17, 2012
• First Submitted That Met QC Criteria: July 18, 2012
• First Posted (Estimate): July 20, 2012

Study Record Updates

• Last Update Posted (Estimate): September 5, 2014
• Last Update Submitted That Met QC Criteria: August 26, 2014
• Last Verified: August 1, 2014

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pain; Neurologic Manifestations; Joint Diseases; Musculoskeletal Diseases; Rheumatic Diseases; Arthritis; Osteoarthritis; Arthralgia; Osteoarthritis, Knee; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Anti-Arrhythmia Agents; Vasodilator Agents; Membrane Transport Modulators; Calcium-Regulating Hormones and Agents; Calcium Channel Blockers; Verapamil
• Other Study ID Numbers: CS-201